Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Phase 2

Age range

18 years - 120 years

Sex eligible

Male

Healthy volunteers

Not accepted

Participants

41 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

• INCLUSION CRITERIA:
• Participants must be male.
• Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.
• Participants must have at least one of the following types of urinary incontinence:

• stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
• urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
• Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.
• Participants must be able to read and write in English.
• Age \>= 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status \<= 2.
• Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

• Change of therapy for prostate cancer planned during the study intervention.
• History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
• Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (\>= 4 UTIs within the 12 months prior to the study treatment initiation).
• History of complete denervation of the pelvic floor.
• Severe obesity (body mass index \[BMI\] \>35).
• Pelvic pain/painful bladder syndrome.
• Metal implant in the abdominal or pelvic area.
• History of chronic cough with ongoing symptoms
• An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
• History of epilepsy.
• History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
• Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
• Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not applicable

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

National Cancer Institute (NCI)

Study start

Feb 15, 2024 Actual

Primary completion

Dec 1, 2027 Estimated

Study completion

Mar 1, 2028 Estimated

First posted

Dec 8, 2023 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts